Table of Contents
EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the acute leukemias market
- Datamonitor insight into the AML market
- Datamonitor insight into the adult ALL market
- Contributing experts
- Related reports
- Upcoming reports
INTRODUCTION AND SCOPE
- Coverage of the Stakeholder Insight Survey
- Disease definition and epidemiology
- Segmentation of the acute leukemia population
- Current drug treatment practice for AML and adult ALL
- Key unmet needs within the AML and adult ALL market
- Overview of pipeline drugs for AML and adult ALL
AML: COUNTRY TREATMENT TREES
- Introduction
- Acute myeloid leukemia (AML) country treatment trees
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
AML: PATIENT SEGMENTATION AND EPIDEMIOLOGY
- Key findings
- Definition of acute myeloid leukemia (AML)
- AML is a disease of older age
- Presentation and diagnosis
- Symptoms can vary for AML patients
- Segmentation of the acute myeloid leukemia (AML) population
- Two classification systems are used in AML
- Cytogenetics is the most important prognostic factor
- Age is a major determinant of survival
- Epidemiology of acute myeloid leukemia (AML)
- AML accounts for about 30 - 35% of all leukemias in the seven major
markets
- Forecast incidence of AML in the seven major markets, 2009 - 2019
AML: TREATMENT TRENDS
- Key findings
- Summary of acute myeloid leukemia (AML) treatment strategies
- Treatment rates
- Induction treatment
- Induction treatment overview
- Induction treatment trends in patients less than 60 years old
- Induction treatment trends in patients aged 60 or above
- Post-induction treatment
- Post-induction treatment overview
- Post-induction treatment trends in patients less than 60 years old
- Post-induction treatment trends in patients aged 60 or above
- Consolidation treatment
- Consolidation treatment overview
- Consolidation treatment trends in patients less than 60 years old
- Consolidation treatment trends in patients aged 60 or above
- Relapse treatment
- Relapse treatment overview
- Relapse treatment trends in patients less than 60 years old
- Relapse treatment trends in patients aged 60 or above
- Hematopoietic stem cell transplantation in acute myeloid leukemia (AML)
AML: IMPROVING TREATMENT OUTCOMES
- Key findings
- Treatment outcomes
- Unmet needs
- More effective therapies are required for AML
- HSCT remains an underutilized procedure
- Molecular markers may help improve risk-adapted therapeutic strategies
- New product development
- A number of new approaches are being investigated in AML
- Novel drugs in Phase III development for AML
- Selected marketed drugs investigated in AML
ALL: COUNTRY TREATMENT TREES
- Introduction
- Acute lymphoblastic leukemia (ALL) country treatment trees
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
ALL: PATIENT SEGMENTATION AND EPIDEMIOLOGY
- Definition of acute lymphoblastic leukemia (ALL)
- ALL represents less than 1% of all adult cancers
- Genetic alterations provide insight into the pathogenesis of ALL
- Presentation and diagnosis
- Non-specific syndromes are common in ALL
- Segmentation of the ALL population
- The classification of ALL is still evolving
- Patients are usually stratified according to risk
- Epidemiology of ALL
- ALL accounts for about 10 - 15% of all leukemias in the seven major
markets
- Forecast incidence of ALL in the seven major markets, 2009 - 2019
ALL: TREATMENT TRENDS
- Summary of acute lymphoblastic leukemia (ALL) treatment strategies
- Treatment rates
- Induction treatment
- Induction treatment overview
- Induction treatment trends
- Consolidation treatment
- Consolidation treatment overview
- Consolidation treatment trends
- Maintenance treatment
- Maintenance treatment overview
- Maintenance treatment trends
- Clinical trials in ALL
- Hematopoietic stem cell transplantation in ALL
ALL: IMPROVING TREATMENT OUTCOMES
- Treatment outcomes
- Unmet needs
- More effective therapies are required for adult ALL
- Research efforts should focus on older ALL patients
- Prognostic markers are required for risk-adapted therapeutic strategies
- New product development
- R&D activity in ALL is limited
- Novel drugs in late-phase development for adult ALL
- Selected marketed drugs investigated in adult ALL
BIBLIOGRAPHY
- Journals
- Websites
- Datamonitor reports
APPENDIX A
- Physician research methodology
- Physician sample breakdown
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
- Contributing experts
APPENDIX B
TABLES
- Table: French-American-British classification of acute myeloid leukemia
(AML)
- Table: Forecast incidence of acute myeloid leukemia (AML) in the seven
major pharmaceutical markets, 2009 - 2019
- Table: Percentage of acute myeloid leukemia (AML) patients less than 60
years old receiving each induction regimen in the seven major pharmaceutical
markets, 2009
- Table: Percentage of acute myeloid leukemia (AML) patients aged 60 or
above receiving each induction regimen in the seven major pharmaceutical
markets, 2009
- Table: Percentage of acute myeloid leukemia (AML) patients less than 60
years old receiving each post-induction regimen/therapy in the seven major
pharmaceutical markets, 2009
- Table: Percentage of acute myeloid leukemia (AML) patients aged 60 or
above receiving each post-induction regimen/therapy in the seven major
pharmaceutical markets, 2009
- Table: Percentage of acute myeloid leukemia (AML) patients less than 60
years old receiving each consolidation regimen/therapy in the seven major
pharmaceutical markets, 2009
- Table: Percentage of acute myeloid leukemia (AML) patients aged 60 or
above receiving each consolidation regimen/therapy in the seven major
pharmaceutical markets, 2009
- Table: Percentage of acute myeloid leukemia (AML) patients less than 60
years old receiving each relapse regimen/therapy in the seven major
pharmaceutical markets, 2009
- Table: Percentage of acute myeloid leukemia (AML) patients aged 60 or
above receiving each relapse regimen/therapy in the seven major pharmaceutical
markets, 2009
- Table: Examples of therapeutic approaches investigated in the treatment of
acute myeloid leukemia (AML)
- Table: Drugs in Phase III development for acute myeloid leukemia (AML),
2009
- Table: Selected marketed drugs in Phase III development for acute myeloid
leukemia (AML), 2009
- Table: The French-American-British system for the classification of acute
lymphoblastic leukemia (ALL)
- Table: Forecast incidence of acute lymphoblastic leukemia (ALL) in the
seven major pharmaceutical markets, 2009 - 2019
- Table: Results from selected clinical studies evaluating Gleevec in the
treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
(ALL) patients
- Table: Percentage of treated adult acute lymphoblastic leukemia (ALL)
patients receiving each induction regimen in the seven major pharmaceutical
markets, 2009
- Table: Percentage of standard-risk, adult acute lymphoblastic leukemia
(ALL) patients receiving each consolidation regimen/therapy in the seven major
pharmaceutical markets, 2009
- Table: Percentage of high-risk, adult acute lymphoblastic leukemia (ALL)
patients receiving each consolidation regimen/therapy in the seven major
pharmaceutical markets, 2009
- Table: Percentage of treated adult acute lymphoblastic leukemia (ALL)
standard-risk patients receiving each maintenance regimen/therapy in the seven
major pharmaceutical markets, 2009
- Table: Percentage of treated adult acute lymphoblastic leukemia (ALL)
high-risk patients receiving each maintenance regimen/therapy in the seven
major pharmaceutical markets, 2009
- Table: Group for Research in Adult ALL (GRAAL) trial group
- Table: Programa para el Estudio de la Terapeutica en Hemopatia Maligna
(PETHEMA) trial group
- Table: German Multicenter Study Group on Adult Acute Lymphoblastic
Leukemia (GMALL) trial group
- Table: New therapeutic strategies evaluated in the treatment of acute
lymphoblastic leukemia (ALL), 2009
- Table: Drugs in late-phase development for adult acute lymphoblastic
leukemia (ALL), 2009
- Table: US physician sample breakdown, 2009
- Table: Japan physician sample breakdown, 20 09
- Table: France physician sample breakdown, 20 09
- Table: Germany physician sample breakdown, 20 09
- Table: Italy physician sample breakdown, 20 09
- Table: Spain physician sample breakdown, 20 09
- Table: UK physician sample breakdown, 20 09
FIGURES
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in the US for patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in the US for patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in the US for patients
less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in the US for patients
aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Japan for patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Japan for patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Japan for patients
less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Japan for patients
aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in France for patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in France for patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in France for patients
less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in France for patients
aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Germany for patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Germany for patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Germany for
patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Germany for
patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Italy for patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Italy for patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Italy for patients
less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Italy for patients
aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Spain for patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in Spain for patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Spain for patients
less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in Spain for patients
aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in the UK for patients less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) incidence and patient segmentation
data in the UK for patients aged 60 or older, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in the UK for patients
less than 60 years old, 2009
- Figure: Acute myeloid leukemia (AML) treatment data in the UK for patients
aged 60 or older, 2009
- Figure: Age distribution of acute myeloid leukemia (AML) patients
- Figure: Percentage distribution of leukemia subtypes in the US, Japan and
the five major EU markets, 2009
- Figure: Average treatment rate for acute myeloid leukemia (AML) patients
less than 60 years old in the seven major pharmaceutical markets, 2009
- Figure: Average treatment rate for acute myeloid leukemia (AML) patients
aged 60 or above in the seven major pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the induction therapy of
acute myeloid leukemia (AML) patients less than 60 years old in the seven
major pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the induction therapy of
acute myeloid leukemia (AML) patients aged 60 or above in the seven major
pharmaceutical markets, 2009
- Figure: Uptake of Dacogen and Vidaza in the treatment of acute myeloid
leukemia (AML) in the US, 2009
- Figure: Top three chemotherapy regimens used in the post-induction therapy
of acute myeloid leukemia (AML) patients less than 60 years old in the seven
major pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the post-induction therapy
of acute myeloid leukemia (AML) patients aged 60 or above in the seven major
pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the consolidation therapy
of acute myeloid leukemia (AML) patients less than 60 years old in the seven
major pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the consolidation therapy
of acute myeloid leukemia (AML) patients aged 60 or above in the seven major
pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the relapse therapy of
acute myeloid leukemia (AML) patients less than 60 years old in the seven
major pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the relapse therapy of
acute myeloid leukemia (AML) patients aged 60 or above in the seven major
pharmaceutical markets, 2009
- Figure: Uptake of Mylotarg in the treatment of acute myeloid leukemia
(AML) in patients aged under 60 and in patients aged 60 or above, 2009
- Figure: Average use of hematopoietic stem cell transplantation (HSCT) in
the induction, post-induction, consolidation, and relapse treatment of AML in
the seven major pharmaceutical markets, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) incidence and patient
segmentation data in the US, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) treatment data in the US,
2009
- Figure: Adult acute lymphoblastic leukemia (ALL) incidence and patient
segmentation data in Japan, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) treatment data in Japan,
2009
- Figure: Adult acute lymphoblastic leukemia (ALL) incidence and patient
segmentation data in France, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) treatment data in France,
2009
- Figure: Adult acute lymphoblastic leukemia (ALL) incidence and patient
segmentation data in Germany, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) treatment data in
Germany, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) incidence and patient
segmentation data in Italy, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) treatment data in Italy,
2009
- Figure: Adult acute lymphoblastic leukemia (ALL) incidence and patient
segmentation data in Spain, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) treatment data in Spain,
2009
- Figure: Adult acute lymphoblastic leukemia (ALL) incidence and patient
segmentation data in the UK, 2009
- Figure: Adult acute lymphoblastic leukemia (ALL) treatment data in the UK,
2009
- Figure: Risk stratification of adult acute lymphoblastic leukemia (ALL)
patients in the seven major pharmaceutical markets, 2009
- Figure: Philadelphia chromosome status in high-risk adult acute
lymphoblastic leukemia (ALL) patients in the seven major pharmaceutical
markets, 2009
- Figure: Percentage distribution of leukemia subtypes in the US, Japan and
the five major EU markets, 2009
- Figure: Age distribution of childhood and adult acute lymphoblastic
leukemia (ALL) in the seven major markets, 2009
- Figure: Average treatment rates for adult acute lymphoblastic leukemia
(ALL) patients in the seven major pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the induction therapy of
adult acute lymphoblastic leukemia (ALL) in the seven major pharmaceutical
markets, 2009
- Figure: Top three chemotherapy regimens used in the consolidation therapy
of standard-risk adult acute lymphoblastic leukemia (ALL) in the seven major
pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the consolidation therapy
of high-risk adult acute lymphoblastic leukemia (ALL) in the seven major
pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the maintenance therapy of
standard-risk adult acute lymphoblastic leukemia (ALL) in the seven major
pharmaceutical markets, 2009
- Figure: Top three chemotherapy regimens used in the maintenance therapy of
high-risk adult acute lymphoblastic leukemia (ALL) in the seven major
pharmaceutical markets, 2009
- Figure: Average use of clinical trials in the induction, consolidation,
and maintenance therapy of adult acute lymphoblastic leukemia (ALL) in the
seven major pharmaceutical markets, 2009
- Figure: Average use of hematopoietic stem cell transplantation in the
consolidation and maintenance therapy of adult acute lymphoblastic leukemia
(ALL) in the seven major pharmaceutical markets, 2009
|
Related Report
|
View Cart
